|Videos|May 27, 2016
An Increased Emphasis on Individual Risk Factors and Goals
Advertisement
Episodes in this series
Zachary T. Bloomgarden, MD, MACE: We talked about lipid-lowering treatment and the notion that the idea of goals has recently been questioned. So, I certainly think that goals are a good way of treating cholesterol, but there are some controversies about that.
We use goals in treating all medical conditions. We use goals in treating blood pressure—we have to decide what the right blood pressure goal is for a given individual and then aim for that. We use goals in treating diabetes—we have to decide what the right A1C goal or fasting plasma glucose goal is for a given individual, and then stay with that. I’m completely in favor of the use of goals, as long as we do it in a rational fashion and apply it correctly.
Advertisement
Related to this article
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Experts explain why access to specialty cancer care, open dialogue, and patient education are essential to building trust and making informed treatment decisions.
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
Rusfertide Keeps Working Where Hydroxyurea Fades: Andrew Kuykendall, MD
3
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
4
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
5